REN and hydrops fetalis: Nowadays, sacubitril-valsartan has accounted for 63.7% of the renin-angiotensin-aldosterone system inhibitors in patients with HF in the report 2020 Clinical Performance and Quality Measures for Heart Failure in China (24).